SUMMER ROAD LLC Portfolio
Auto-discovered active 13F filer.
SEC 13F CIK: 0001604873
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q3 2023 · 1 positions · Total reported value $19.22M · Top-10 concentration 100.0% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 30.8% · 5 new · 0 cut · 3 exited
Active Share (vs S&P 500): 99.5% · vs QQQ: 99.8% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -17.5% · vs SPY -19.6% · Prev Value $161.01M — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -6.8% · vs SPY -8.9% · Latest Value $135.17M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q3 2023 13F filing, SUMMER ROAD LLC disclosed 1 equity positions with a combined reported value of $19.22M. The filing implies a focused portfolio: its ten largest positions account for 100.0% of reported value. HoldingsHub classifies the profile as Small / Focused / Health Tilt / High Turnover.
The largest disclosed positions as of Q3 2023 were OCUL ($19.22M). By sector, the heaviest allocations are Health Care 100.0%.
Versus the prior quarter, SUMMER ROAD LLC opened 5 new positions, trimmed 0 and fully exited 3, a turnover rate of 30.8% of positions.
The largest new positions opened in Q3 2023 were OCUL ($19.22M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q3 2023)
- OCUL OCULAR THERAPEUTIX INC · $19.22M
Fully Exited (vs previous quarter)
No tracked position was fully exited this quarter.
Insider Transactions (Form 4)
Latest SUMMER ROAD LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Summer Road files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 21 positions worth $161.01M in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 21 positions · $161.01M reported value (Q2 2026)
- Top 10 holdings = 99.7% of reported value
- Largest position: OCUL (OCULAR THERAPEUTIX INC) at 74.5%
- Average position size: $7.67M
Sector Tilt
- Health Care 74.5%
- Consumer Staples 23.9%
- Real Estate 0.7%
- (classified holdings cover 100% of value)
Quarterly Activity
- Q2 2026: 2 new, 3 added, 2 reduced, 5 exited
- 14 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
FAQ
What did SUMMER ROAD LLC buy in 2023-Q3?
In its 2023-Q3 13F filing, SUMMER ROAD LLC reported 1 equity positions worth $19.22M in aggregate; its largest disclosed positions were OCUL ($19.22M).
How large is SUMMER ROAD LLC's portfolio?
SUMMER ROAD LLC reported $19.22M of long equity holdings across 1 positions as of 2023-Q3. Top-10 holdings account for 100.0% of reported value.
What is SUMMER ROAD LLC's investment style?
HoldingsHub classifies the portfolio as Small / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.